WASHINGTON, D.C.—The American Pharmacists Association (APhA) issued the following statement in response to plans and payers, including PBMs, setting the dispensing fee for new COVID‐19 oral antiviral therapies below pharmacies’ costs to dispense these lifesaving medications: